Comprehensive Bariatric & Metabolic Surgical Sciences

Obesity is a complex, progressive, and multi-factorial chronic disease defined by excessive adiposity that impairs health. It is not a lifestyle flaw or a simple consequence of overeating. When an individual reaches Class II or Class III obesity, the body's metabolic "set point" shifts structurally, making long-term weight reduction through conventional calorie restriction and exercise statistically baseline-ineffective for over 95% of individuals due to powerful compensatory neuroendocrine mechanisms.

Dr. Rohith Garg, utilizing his specialized Fellowship in Bariatric & Metabolic Surgery (FBMS), provides advanced, micro-incision laparoscopic options. These interventions do not simply create mechanical barriers to eating; they actively reset the patient's metabolic architecture, alter gut-brain signaling, suppress chronic inflammatory profiles, and stimulate long-term remission of severe metabolic comorbidities.

Strict Clinical Eligibility & Indications (IFSO & OSSI Guidelines)

In accordance with the International Federation for the Surgery of Obesity (IFSO) and the Obesity Surgery Society of India (OSSI) consensus guidelines, surgical intervention is indicated for patients who meet the following body mass index (BMI) or comorbidity thresholds:

• BMI ≥ 35 kg/m²: Indicated as a primary therapeutic intervention, regardless of the presence or absence of secondary medical comorbidities.
• BMI 30.0 – 34.9 kg/m²: Recommended in the presence of severe, weight-accelerated medical conditions such as uncontrolled Type 2 Diabetes Mellitus (T2DM), severe obstructive sleep apnea (OSA), coronary artery disease, non-alcoholic steatohepatitis (NASH), or debilitating degenerative joint disease.
• BMI ≥ 27.5 kg/m² (Asian-Specific Threshold): Because individuals of South Asian descent exhibit a higher percentage of visceral adipose tissue and an increased genetic predisposition to insulin resistance at lower absolute body weights, metabolic surgery is clinically approved for Asian patients struggling with poorly controlled Type 2 Diabetes at this lower threshold.

1. Laparoscopic Sleeve Gastrectomy (LSG)

Laparoscopic Sleeve Gastrectomy is a primary, non-reversible restrictive procedure. Operating through 4 to 5 keyhole ports, Dr. Garg removes approximately 75% to 80% of the gastric volume, transforming the stomach from a distensible sac into a narrow, calibrated tube or "sleeve" along the lesser curvature, structured over a sizing bougie (typically 36Fr to 40Fr).

Physiological and Hormonal Mechanisms:

• Mechanical Restriction: Gastric capacity is safely reduced from approximately 1.5 liters to roughly 100-150 milliliters, inducing early, physical satiety with small food volumes.
• Neuroendocrine Regulation (Ghrelin Suppression): The fundus of the stomach—which contains the cells responsible for synthesizing Ghrelin (the hunger hormone)—is completely resected. This drops systemic Ghrelin levels instantly, eliminating baseline chemical cravings, quiet hunger pangs, and mental food anxiety.
• Accelerated Gastric Emptying: The narrowed tube speeds up the transit of food into the duodenum, stimulating early release of hindgut hormones like peptide YY (PYY) that signal full satiety directly to the brain.

2. Laparoscopic Roux-en-Y Gastric Bypass (LRYGB)

The Roux-en-Y Gastric Bypass is the historic "gold standard" macro-metabolic intervention, combining mechanical restriction with targeted nutrient malabsorption. Dr. Garg resects the upper stomach to construct a small, isolated gastric pouch (approximately 30cc in volume). The small intestine is then divided; the distal limb (Roux limb) is brought up and surgically connected to the pouch (Gastrojejunostomy). The proximal limb carrying digestive juices is re-attached further down (Jejunojejunostomy), creating a Y-shaped structural assembly.

Clinical Indications & Endocrine Remission:

This path completely bypasses the remaining stomach, the duodenum, and the proximal jejunum. It is highly indicated for patients suffering from severe, long-standing Type 2 Diabetes or chronic, erosive Gastroesophageal Reflux Disease (GERD). The bypass avoids tissue irritation within the lower esophageal sphincter and stops acid production within the active digestive tract path.

• The Incretin Effect (Direct Diabetes Remission): Bypassing the foregut triggers an immediate, massive surge in Glucagon-Like Peptide-1 (GLP-1) and PYY secreted by the hindgut. This directly enhances pancreatic beta-cell insulin sensitivity and stabilizes glucose levels within days of surgery—long before significant fat loss occurs.
• Controlled Malabsorption: Shortening the functional nutrient absorption pathway guarantees excellent, long-term weight maintenance and limits caloric over-absorption.

3. Laparoscopic Mini Gastric Bypass / One Anastomosis Gastric Bypass (OAGB)

The Mini Gastric Bypass (MGB/OAGB) is a modern alternative that simplifies the traditional Roux-en-Y setup down to a single surgical loop connection. Dr. Garg creates a long, narrow, tube-like stomach pouch, similar to a sleeve gastrectomy but preserving the lower pathways. A loop of the small intestine is then brought up and joined directly to this tube at a point roughly 150 to 200 cm down the bowel line, bypassing the upper intestine completely.

Surgical Benefits & Metabolic Potency:

• Reduced Operative Risk: By requiring only a single surgical join (anastomosis) instead of two, the procedure limits complex operating time and reduces the risk of long-term internal hernias.
• Exceptional Weight Loss & Resolution: The substantial malabsorptive bypass loop delivers excellent, sustained weight loss results and acts as a powerful anti-diabetic intervention.

Metabolic Surgery Core Profile (Type 2 Diabetes Resolution)

When these procedures are performed primarily to treat metabolic diseases rather than absolute obesity, the protocol is called Metabolic Surgery. Clinical studies confirm that metabolic surgery yields up to 85% complete long-term remission of Type 2 Diabetes, radically outperforming intensive medical management. Bypassing the foregut and delivering nutrients quickly to the hindgut permanently resets systemic insulin resistance pathways.

Comprehensive Post-Operative Nutritional Phases

To support proper tissue healing along the delicate surgical stitch lines, all bariatric patients follow a strict, phased dietary progression managed by our specialized nutritional team:

Timeline	Dietary Phase	Clinical Focus & Permitted Items
Days 1 – 7	Clear Liquid Diet	Small, frequent sips of coconut water, clear broth, strained apple juice, and water to maximize hydration without stress on staple lines.
Weeks 2 – 3	Full Liquid / Pureed Diet	High-protein shakes, thin pureed dals, and strained soups. Focus shifts to achieving 60g of daily protein intake.
Weeks 4 – 6	Soft Solid Diet	Mashed vegetables, soft boiled eggs, paneer, and thoroughly cooked soft fish. Minimal chewing pressure required.
Week 7 Onward	Regular Solid Diet	Clean, solid whole foods. Strict rules include separating solids and liquids by 30 minutes, prioritizing protein first, and avoiding refined carbohydrates.

Sleeve Gastrectomy vs. Gastric Bypass

Understanding which procedure is right for you requires a detailed consultation with Dr. Garg. Here is a baseline comparative matrix:

Feature	Sleeve Gastrectomy	Roux-en-Y Bypass
Mechanism	Purely Restrictive	Restrictive + Malabsorptive
Expected Excess Weight Loss	60% - 70% over 12-18 months	70% - 80% over 12-18 months
Diabetes Resolution Rate	High (~60-70% remission)	Extremely High (~80-90% remission)
Anatomical Alteration	Stomach resected; intestines untouched	Stomach remains; path rerouted
GERD Impact	May worsen in patients with hiatal laxity	Highly therapeutic for severe GERD

Frequently Asked Questions